
Citius Pharmaceuticals CTXR
$ 0.55
0.0%
Citius Pharmaceuticals ROE Ratio | CTXR
Annual ROE Ratio Citius Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -58.83 | -56.26 | -35.83 | -32.72 | -17.44 | -52.12 | -63.84 | -44.99 | -47.32 | -49.48 | 456.9 | - | - | - | - | -620.0 |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 456.9 | -620.0 | -51.83 |
Quarterly ROE Ratio Citius Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -83.32 | -56.62 | -59.79 | -48.04 | -60.3 | -56.83 | -48.67 | -33.76 | -8659.72 | -8658.93 | -8651.8 | -8640.98 | -8665.93 | -48.0 | -42.93 | -46.78 | -35.52 | -31.73 | -28.61 | -52.78 | -78.98 | -88.63 | -117.66 | -104.75 | -108.75 | -116.47 | -105.37 | -101.08 | -97.29 | -84.03 | -78.84 | -77.02 | -70.39 | -73.07 | -69.6 | -71.39 | -59.51 | -61.45 | 27.87 | 42.22 | 356.12 | 507.56 | 712.72 | 735.97 | 510.97 | 385.79 | 304.64 | 223.04 | 347.62 | 556.4 | 447.81 | 429.48 | 263.99 | 98.51 | 99.09 | 99.24 | 161.73 | 224.22 | 230.94 | 110.49 | 110.49 | 9.72 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 735.97 | -8665.93 | -622.24 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Curis
CRIS
|
-138.81 | $ 0.88 | 3.67 % | $ 11.6 M | ||
|
Cyclerion Therapeutics
CYCN
|
-46.78 | $ 34.99 | 3.77 % | $ 147 M | ||
|
Завод ДИОД
DIOD
|
3.1 | - | - | - | ||
|
CorMedix
CRMD
|
40.23 | $ 5.31 | 1.43 % | $ 383 K | ||
|
Novartis AG
NVS
|
30.0 | $ 162.64 | 0.44 % | $ 315 B | ||
|
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 50.09 | 3.15 % | $ 4.5 B | ||
|
PDS Biotechnology Corporation
PDSB
|
-81.75 | $ 1.22 | 4.27 % | $ 56.6 M | ||
|
Pfizer
PFE
|
8.99 | $ 29.39 | -0.22 % | $ 167 B | ||
|
Pharming Group N.V.
PHAR
|
22.12 | $ 12.32 | 0.16 % | $ 8.49 B | ||
|
Orgenesis
ORGS
|
128.44 | - | -33.86 % | $ 61.2 M | ||
|
Cytokinetics, Incorporated
CYTK
|
119.0 | $ 53.74 | -3.26 % | $ 6.45 M | ||
|
Фармсинтез
LIFE
|
-51.75 | - | - | - | ||
|
Prothena Corporation plc
PRTA
|
-87.03 | $ 7.93 | 0.51 % | $ 427 M | ||
|
Codiak BioSciences
CDAK
|
-69.45 | - | -55.98 % | $ 2.15 M | ||
|
DBV Technologies S.A.
DBVT
|
-87.07 | $ 10.54 | 7.55 % | $ 1.47 B | ||
|
Rocket Pharmaceuticals
RCKT
|
-80.49 | $ 2.38 | -2.05 % | $ 264 M | ||
|
Regeneron Pharmaceuticals
REGN
|
14.41 | $ 904.69 | 0.2 % | $ 94.6 B | ||
|
Replimune Group
REPL
|
-188.91 | $ 21.67 | 8.24 % | $ 2.01 B | ||
|
DiaMedica Therapeutics
DMAC
|
-58.39 | $ 9.47 | 4.76 % | $ 445 M | ||
|
Royalty Pharma plc
RPRX
|
7.94 | $ 67.31 | -0.39 % | $ 28.9 B | ||
|
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | ||
|
Rhythm Pharmaceuticals
RYTM
|
-0.14 | $ 111.51 | 6.18 % | $ 7.25 B | ||
|
Puma Biotechnology
PBYI
|
23.87 | $ 8.28 | -15.25 % | $ 414 M | ||
|
SIGA Technologies
SIGA
|
11.71 | $ 3.12 | 4.55 % | $ 223 M | ||
|
Sage Therapeutics
SAGE
|
-86.15 | - | - | $ 527 M | ||
|
Taro Pharmaceutical Industries Ltd.
TARO
|
1.47 | - | - | $ 1.62 B | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
-26.86 | $ 61.62 | -2.21 % | $ 172 M | ||
|
SELLAS Life Sciences Group
SLS
|
-37.9 | $ 8.41 | 6.73 % | $ 917 M | ||
|
Summit Therapeutics
SMMT
|
-163.86 | $ 16.34 | 15.15 % | $ 12.2 B | ||
|
Cabaletta Bio
CABA
|
-149.81 | $ 1.3 | 1.17 % | $ 131 M | ||
|
Syndax Pharmaceuticals
SNDX
|
-441.62 | $ 9.53 | 1.39 % | $ 826 M | ||
|
Sanofi
SNY
|
10.95 | $ 47.06 | 0.32 % | $ 57.4 B | ||
|
Forma Therapeutics Holdings
FMTX
|
-34.71 | - | - | $ 958 M | ||
|
Blueprint Medicines Corporation
BPMC
|
-22.46 | - | - | $ 8.14 B | ||
|
Horizon Therapeutics Public Limited Company
HZNP
|
10.28 | - | - | $ 26.6 B | ||
|
Sarepta Therapeutics
SRPT
|
-62.55 | $ 17.8 | 0.68 % | $ 1.78 B | ||
|
Paratek Pharmaceuticals
PRTK
|
37.16 | - | - | $ 121 M | ||
|
China SXT Pharmaceuticals
SXTC
|
-20.89 | $ 2.84 | -3.07 % | $ 1.93 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
1.56 | $ 21.02 | -0.92 % | $ 33.2 B | ||
|
Tarsus Pharmaceuticals
TARS
|
-19.22 | $ 68.11 | 0.87 % | $ 2.85 B | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
332.81 | - | -14.27 % | $ 1.7 M | ||
|
Bio-Techne Corporation
TECH
|
8.63 | $ 72.78 | 0.17 % | $ 11.4 B | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
17.83 | $ 42.32 | 1.33 % | $ 48.5 B | ||
|
RedHill Biopharma Ltd.
RDHL
|
176.55 | $ 0.43 | 0.45 % | $ 5.3 B | ||
|
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | ||
|
Unity Biotechnology
UBX
|
-400.22 | - | -33.41 % | $ 3.37 M | ||
|
iTeos Therapeutics
ITOS
|
-22.77 | - | - | $ 411 M | ||
|
Shattuck Labs
STTK
|
-59.24 | $ 4.59 | 2.78 % | $ 319 M | ||
|
Seelos Therapeutics
SEEL
|
113.05 | - | -47.76 % | $ 6.27 M | ||
|
Evogene Ltd.
EVGN
|
-65.36 | $ 0.28 | -16.14 % | $ 2.2 M |